)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Genomtec
Genomtec (GMT) investor relations material
Genomtec Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary30 Sep, 2026
Executive summary
Group continued R&D activities in biotechnology and medical devices, focusing on the Genomtec ID diagnostic platform, which is in the industrialization phase with an external partner.
No seasonality or cyclicality in operations; business is funded by equity, grants, and recent share issuance.
Group structure unchanged; 100% ownership in two subsidiaries focused on scientific research.
Financial highlights
Consolidated revenue from sales: 27k PLN for H1 2026, unchanged year-over-year.
Net loss for H1 2026: (4,267)k PLN, improved from (6,555)k PLN in H1 2025.
Cash and equivalents at period end: 14,244k PLN, up from 4,722k PLN at 2025 year-end.
Equity increased to 15,671k PLN from 9,214k PLN at 2025 year-end, mainly due to new share issuance.
Outlook and guidance
Management expects continued negative results and cash outflows until commercialization of developed technologies.
Additional capital may be raised through further share issues to finance commercialization.
Group aims to reach break-even after successful commercialization.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Genomtec
- Net loss narrowed and revenue rose, but continued funding and market risks persist.GMT
Q1 2026 - Patent expansion, cost cuts, and narrowed loss set the stage for commercialization in 2026.GMTQ4 2025
- Net loss widened to PLN -11.2m as R&D continued, with equity raises ensuring 12+ months liquidity.GMTQ4 2024
- Net loss persists as R&D spending rises; commercialization and funding remain critical.GMTQ3 2025
- Rapid genetic diagnostics, strong IP, and robust funding drive growth and M&A momentum.GMTInvestor Presentation
- Net loss deepened to PLN 6.6M as R&D spending rose; commercialization still ahead.GMTQ2 2025
- Genomtec ID and OncoSNAAT are positioned for separate sales as projects advance.GMTInvestor Update
- Losses persist as Genomtec advances R&D, secures funding, and pursues M&A for commercialisation.GMTQ3 2024
- Net loss widened to PLN 6.0 million in H1 2024 as Genomtec advanced R&D and raised new capital.GMTQ2 2024
Next Genomtec earnings date
Q3 202630 Nov, 2026
Genomtec
Next Genomtec earnings date
Q3 202630 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Genomtec S.A. is a biotechnology company specializing in molecular diagnostics. The company develops and commercializes portable and laboratory-based diagnostic solutions using isothermal nucleic acid amplification technology. Its products are designed for rapid and precise detection of infectious diseases, genetic disorders, and other medical conditions. The company is headquartered in Wrocław, Poland, and its shares are listed on the WSE.